Страна: Швеция
Език: шведски
Източник: Läkemedelsverket (Medical Products Agency)
bilastin
Alfred E Tiefenbacher (GmbH & Co. KG)
R06AX29
bilastine
20 mg
Tablett
bilastin 20 mg Aktiv substans; mannitol Hjälpämne
Receptbelagt
Förpacknings: Blister, 6 tabletter (Al); Blister, 6 tabletter (plast/Al); Blister, 10 tabletter (Al); Blister, 10 tabletter (plast/Al); Blister, 100 tabletter (Al); Blister, 100 tabletter (plast/Al); Blister, 20 tabletter (Al); Blister, 20 tabletter (plast/Al); Blister, 30 tabletter (Al); Blister, 30 tabletter (plast/Al); Blister, 50 tabletter (Al); Blister, 50 tabletter (plast/Al)
Godkänd
2022-03-11
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Bilata 20 mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 20 mg of bilastine. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablet. Round, white to off-white biconvex, tablets of approximately 7 mm in diameter. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria.is indicated in adults and adolescents (12 years of age and over). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY _Adults and adolescents (12 years of age and over)_ 20 mg bilastine (1 tablet) once daily for the relief of symptoms of allergic rhinoconjunctivitis (SAR and PAR) and urticaria. The tablet should be taken one hour before or two hours after intake of food or fruit juice (see section 4.5). Duration of treatment: For allergic rhino-conjunctivitis the treatment should be limited to the period of exposure to allergens. For seasonal allergic rhinitis treatment could be discontinued after the symptoms have resolved and reinitiated upon their reappearance. In perennial allergic rhinitis continued treatment may be proposed to the patients during the allergen exposure periods. For urticaria the duration of treatment depends on the type, duration and course of the complaints. _Special populations_ Elderly No dosage adjustments are required in elderly patients (see section 5.1 and 5.2). Renal impairment Studies conducted in adults in special risk groups (renally impaired patients) indicate that it is not necessary to adjust the dose of Прочетете целия документin adults (See section 5.2). Hepatic impairment There is no clinical experience in patients with hepatic impairment. However, since bilastine is not metabolized and is eliminated as unchanged in urine and faeces, hepatic impairment is not expected to increase systemic exposure above the safety margin in adult patients. Therefore, no dosage adjustment is required in patients with he